The Race to Own Alzheimer’s: New Therapies Reshape Market
Alzheimer’s treatment is no longer about managing decline; it’s becoming a race to slow, detect and intervene earlier than ever before. What was once a market defined by symptomatic care is now being transformed by disease-modifying therapies, new delivery models and a more complex competitive landscape.
According to Visiongain analysis, the global Alzheimer’s therapeutics market is valued at US$6.75 billion in 2026 and is projected to grow at a CAGR of 18.2%, reaching US$35.76 billion by 2036.
Visiongain Top Takeaways
Request sample pages to explore the key forces shaping market growth.
Disease-Modifying Therapies Set to Change the Market Structure
For decades, Alzheimer’s treatment focused on managing symptoms. Cholinesterase inhibitors and NMDA receptor antagonists offered modest benefit but did not alter disease progression.
The approval of anti-amyloid therapies from companies such as Eisai, Biogen and Eli Lilly has created a new category of treatment aimed at slowing disease progression, particularly in earlier-stage patients.
This is already changing how value is created in the market. Although patient volumes remain relatively limited, disease-modifying therapies are driving disproportionate value growth. Pricing, reimbursement models and care pathways are all adapting to support these therapies.
At the same time, symptomatic treatments remain widely used. Drugs such as donepezil continue to play a central role due to their affordability and ease of use, creating a more complex market structure in which multiple treatment types coexist.
Delivery Innovation Expands Patient Access
How therapies are delivered is becoming as important as the therapies themselves.
Recent developments, including Eisai’s subcutaneous formulation of lecanemab and ongoing work from Biogen, highlight how delivery innovation is becoming a key competitive factor. Moving beyond infusion-based administration could reduce reliance on specialist infrastructure and expand access.
At-home or simplified delivery models can reduce operational burden for healthcare systems and improve continuity of care, particularly in regions with limited neurology capacity.
Improved delivery also has implications for adherence and long-term outcomes. Simplifying treatment administration can support sustained use over time, which is critical for disease-modifying therapies.
Pipeline Broadens Beyond Amyloid
While anti-amyloid therapies are driving the current wave of market change, the pipeline is already evolving beyond this approach.
Research activity is increasingly focused on alternative mechanisms, including tau protein aggregation, neuroinflammation and synaptic dysfunction. This reflects a move towards targeting Alzheimer’s through multiple biological pathways.
Investment activity reflects this direction. Novartis’ licensing agreement with SciNeuro highlights growing interest in next-generation delivery technologies designed to improve brain penetration and differentiate from existing therapies.
Combination approaches are also emerging, with companies exploring therapies that target multiple disease mechanisms simultaneously. These strategies aim to deliver more durable clinical benefit than single-pathway treatments.
Diagnostics Become a Market Enabler
Earlier intervention is central to the success of disease-modifying therapies, increasing the importance of diagnostics and patient identification.
Advances in blood-based biomarker testing are enabling earlier and more accessible diagnosis. These developments are expanding the pool of eligible patients and enabling earlier intervention.
Earlier diagnosis increases treatment duration per patient and supports the case for long-term reimbursement models.
Competitive Landscape Grows More Complex
The Alzheimer’s therapeutics market is becoming more intricate, with competition now spanning therapies, delivery models and diagnostics.
Leading companies, including Roche, Eli Lilly, Biogen Eisai and Novartis, are increasing investment across disease-modifying therapies, delivery innovation and next-generation mechanisms. At the same time, they must maintain established symptomatic treatment portfolios.
This is increasing competitive intensity. Competition for access to new mechanisms, technologies and partnerships is intensifying as companies seek to secure long-term positioning.
Companies that can operate across multiple parts of the value chain are likely to be better positioned than those focused on a single segment.
Market Outlook Signals Growth with Fundamental Change
The Alzheimer’s therapeutics market is expected to grow significantly over the next decade, supported by strong unmet need and continued innovation.
Value is shifting towards disease-modifying therapies, earlier diagnosis and more accessible delivery models. In parallel, reimbursement, infrastructure and long-term outcomes will play a larger role in determining commercial success.
Regional dynamics will also shape market development. While the United States leads in adoption, Europe and Asia-Pacific markets remain at earlier stages of reimbursement and infrastructure readiness, creating uneven growth patterns.
From Visiongain
Visiongain’s latest Alzheimer’s Therapeutics Market Report 2026–2036 examines how structural constraints, delivery models and innovation are reshaping competitive positioning.
To see where real market growth will emerge and how leading organisations are positioning to capture long-term value, request sample pages.
Latest Reports
Detailed market forecasts, competitive analysis, and sector reports help you make clear, future-proof strategic choices across R&D, manufacturing, supply chain, and commercial execution.
Press & Media Enquiries
For commentary, data requests or interview enquiries, please contact: press@visiongain.com
